UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

Neurology, 2014-04, Vol.82 (17), p.1536-1542

2014

Volltextzugriff (PDF)

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study

Clinical neuropharmacology, 2013, Vol.36 (1), p.14-23

2013

Volltextzugriff (PDF)

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease

Alzheimer's research & therapy, 2016-03, Vol.8 (1), p.12-12, Article 12

2016

Volltextzugriff (PDF)

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

Clinical neuropharmacology, 2013, Vol.36 (1), p.8-13

2013

Volltextzugriff (PDF)

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

International journal of clinical pharmacology and therapeutics, 2013-12, Vol.51 (12), p.911

2013

Volltextzugriff (PDF)

Pharmacokinetics of ponezumab (PF-04360365) following a single-dose intravenous infusion in Japanese patients with mild-to-moderate Alzheimer's disease: Preliminary results

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S305-S305

2010

Volltextzugriff (PDF)

Safety of the anti-amyloid monoclonal antibody ponezumab (PF-04360365) following a single-dose intravenous infusion in Japanese patients with mild-to-moderate Alzheimer's disease: Preliminary results

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S310-S310

2010

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of ponezumab (PF-04360365) following a single-dose intravenous infusion in patients with mild to moderate Alzheimer's disease

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S143-S143

2010

Volltextzugriff (PDF)

Safety and Pharmacokinetics Following a Single Infusion of the Anti-amyloid Monoclonal Antibody Ponezumab (pf-04360365) in Patients With Mild-to-moderate Alzheimer's Disease: Final Results

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.e57-e57

2010

Volltextzugriff (PDF)

Safety and pharmacokinetics of the anti-amyloid monoclonal antibody PF-04360365 following a single infusion in patients with mild-to-moderate Alzheimer's disease: Preliminary results

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P157-P157

2009

Volltextzugriff (PDF)

Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P253-P253

2009

Volltextzugriff (PDF)

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

International journal of clinical pharmacology and therapeutics, 2013-12, Vol.51 (12), p.911-923

2013

Volltextzugriff (PDF)

P1‐440: Pharmacokinetics of ponezumab (PF‐04360365) following a single‐dose intravenous infusion in Japanese patients with mild‐to‐moderate Alzheimer's disease: Preliminary results

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_10), p.S305-S305

2010

Volltextzugriff (PDF)

P1‐454: Safety of the anti‐amyloid monoclonal antibody ponezumab (PF‐04360365) following a single‐dose intravenous infusion in Japanese patients with mild‐to‐moderate Alzheimer's disease: Preliminary results

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_10), p.S310-S310

2010

Volltextzugriff (PDF)

O4‐04‐03: Safety and pharmacokinetics of the anti‐amyloid monoclonal antibody PF‐04360365 following a single infusion in patients with mild‐to‐moderate Alzheimer's disease: Preliminary results

Alzheimer's & dementia, 2009-07, Vol.5 (4S_Part_5), p.P157-P157

2009

Volltextzugriff (PDF)

O3‐07‐05: Pharmacokinetics and pharmacodynamics of ponezumab (PF‐04360365) following a single‐dose intravenous infusion in patients with mild to moderate Alzheimer's disease

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_5), p.S143-S143

2010

Volltextzugriff (PDF)

P4‐118: Safety and Pharmacokinetics Following a Single Infusion of the Anti‐amyloid Monoclonal Antibody Ponezumab (pf‐04360365) in Patients With Mild‐to‐moderate Alzheimer's Disease: Final Results

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_21), p.e57-e57

2010

Volltextzugriff (PDF)

P1‐262: Preliminary population pharmacokinetic modeling of PF‐04360365, a humanized anti‐amyloid monoclonal antibody, in patients with mild‐to‐moderate Alzheimer's disease

Alzheimer's & dementia, 2009-07, Vol.5 (4S_Part_8), p.P253-P253

2009

Volltextzugriff (PDF)

Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Journal of clinical pharmacology, 1995-11, Vol.35 (11), p.1060-1066

1995

Volltextzugriff (PDF)

Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial

JAMA : the journal of the American Medical Association, 1996-08, Vol.276 (7), p.538

1996

Volltextzugriff (PDF)

Exercise testing in asymptomatic young men

The New England journal of medicine, 1986-02, Vol.314 (9), p.579-581

1986

Volltextzugriff (PDF)

Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: Immunomodulation by the cAMP‐PKA pathway

Hepatology (Baltimore, Md.), 2013-03, Vol.57 (3), p.1225-1237

2013

Volltextzugriff (PDF)

Vasoactive intestinal peptide attenuates liver ischemia/reperfusion injury in mice via the cyclic adenosine monophosphate–protein kinase a pathway

Liver transplantation, 2013-09, Vol.19 (9), p.945-956

2013

Volltextzugriff (PDF)

Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (16), p.7194-7204

2005

Volltextzugriff (PDF)

DAMP—Induced Allograft and Tumor Rejection: The Circle Is Closing

American journal of transplantation, 2016-12, Vol.16 (12), p.3322-3337

2016

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Neurology
(14)
Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Male
(11)
Humans
(10)
Biological And Medical Sciences
(7)
Female
(7)
Medical Sciences
(7)
Middle Aged
(7)
Aged
(6)
Pharmacology. Drug Treatments
(6)
Alzheimer Disease - Drug Therapy
(5)
Adult And Adolescent Clinical Studies
(4)
Aged, 80 And Over
(4)
Alzheimer's Disease
(4)
Animals
(4)
Antibodies, Monoclonal, Humanized - Adverse Effects
(4)
Clinical Neurology
(4)
Double-Blind Method
(4)
Immunotherapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

Pharmacokinetics of ponezumab (PF-04360365) following a single-dose intravenous infusion in Japanese patients with mild-to-moderate Alzheimer's disease: Preliminary results

Safety of the anti-amyloid monoclonal antibody ponezumab (PF-04360365) following a single-dose intravenous infusion in Japanese patients with mild-to-moderate Alzheimer's disease: Preliminary results

Pharmacokinetics and pharmacodynamics of ponezumab (PF-04360365) following a single-dose intravenous infusion in patients with mild to moderate Alzheimer's disease

Safety and Pharmacokinetics Following a Single Infusion of the Anti-amyloid Monoclonal Antibody Ponezumab (pf-04360365) in Patients With Mild-to-moderate Alzheimer's Disease: Final Results

Safety and pharmacokinetics of the anti-amyloid monoclonal antibody PF-04360365 following a single infusion in patients with mild-to-moderate Alzheimer's disease: Preliminary results

Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

P1‐440: Pharmacokinetics of ponezumab (PF‐04360365) following a single‐dose intravenous infusion in Japanese patients with mild‐to‐moderate Alzheimer's disease: Preliminary results

P1‐454: Safety of the anti‐amyloid monoclonal antibody ponezumab (PF‐04360365) following a single‐dose intravenous infusion in Japanese patients with mild‐to‐moderate Alzheimer's disease: Preliminary results

O4‐04‐03: Safety and pharmacokinetics of the anti‐amyloid monoclonal antibody PF‐04360365 following a single infusion in patients with mild‐to‐moderate Alzheimer's disease: Preliminary results

O3‐07‐05: Pharmacokinetics and pharmacodynamics of ponezumab (PF‐04360365) following a single‐dose intravenous infusion in patients with mild to moderate Alzheimer's disease

P4‐118: Safety and Pharmacokinetics Following a Single Infusion of the Anti‐amyloid Monoclonal Antibody Ponezumab (pf‐04360365) in Patients With Mild‐to‐moderate Alzheimer's Disease: Final Results

P1‐262: Preliminary population pharmacokinetic modeling of PF‐04360365, a humanized anti‐amyloid monoclonal antibody, in patients with mild‐to‐moderate Alzheimer's disease

Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial

Exercise testing in asymptomatic young men

Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: Immunomodulation by the cAMP‐PKA pathway

Vasoactive intestinal peptide attenuates liver ischemia/reperfusion injury in mice via the cyclic adenosine monophosphate–protein kinase a pathway

Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model

DAMP—Induced Allograft and Tumor Rejection: The Circle Is Closing

Suchergebnisse filtern